Clinical Trial Update: Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating low-intensity chemotherapy plus venetoclax for relapsed or refractory B-cell and T-cell acute lymphoblastic leukemia; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Venetoclax (Venclexta) (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING